Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Overview
This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
Full Title of Study: “A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: September 6, 2023
Interventions
- Drug: ALKS 3831
- Olanzapine + samidorphan, daily oral dosing
Arms, Groups and Cohorts
- Experimental: ALKS 3831
- Coated bilayer tablet
Clinical Trial Outcome Measures
Primary Measures
- Safety will be measured by frequency of serious and non-serious adverse events
- Time Frame: Up to 48 months
Participating in This Clinical Trial
Inclusion Criteria
- Willing and able to give informed consent/assent as per local requirements – Agrees to use an acceptable method of contraception during the study, and for 30 days after any study drug administration, unless surgically sterile or post-menopausal – Has the potential to benefit from the administration of ALKS 3831, in the opinion of the investigator – Subject met the eligibility criteria of the antecedent study at the time of enrollment in the antecedent study and completed the treatment period in one of the following antecedent studies within 7 days: ALK3831-A304, ALK3831-A306, or ALK3831-A307 – Additional criteria may apply Exclusion Criteria:
- Has any finding that, in the view of the investigator or medical monitor, would compromise the safety of the subject or affect their ability to fulfill the protocol visit schedule or visit requirements – Has a positive drug screen for drugs of abuse at study entry – Currently pregnant or breastfeeding or is planning to become pregnant during the study or within 30 days of the last study drug administration – Additional criteria may apply
Gender Eligibility: All
Minimum Age: 16 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Alkermes, Inc.
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Alkermes Medical Director, Study Director, Alkermes, Inc.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.